1. International Diabetes Federation: IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021: https://diabetesatlas.org/. Accessed on March 01, 2022.
2. Diabetes Branch of Chinese Medical Association: Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition). Chin J Endocrinol Metab. 2021;37:311–98.
3. Sanofi. Soliqua®: US prescribing information. 2019. Accessed March 2023. https://products.sanofi.us/soliqua100-33/soliqua100-33.pdf.
4. Sanofi. Suliqua®: EU summary of product characteristics. 2020. Accessed March 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/suliqua.
5. Blonde L, Anderson JE, Chava P, Dendy JA. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019;35:793–804.